BLOOD 2022: Low-Dose Lenalidomide + Accelerated Immunosuppression Withdrawal Examined in Post-Allogeneic HSCT Patients With AML, MDS
Post-allogeneic hematopoietic stem cell transplant patients undergoing maintenance therapy had high disease relapse, graft-versus-host disease rates
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.